Combination antiretroviral studies for patients with primary biliary cirrhosis

World Journal of Gastroenterology

Volumn 22, Issue 1, 2016, Pages 349-360

  Lytvyak, Ellina ^a   Montano Loza, Aldo J ^a   Mason, Andrew L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antiretroviral therapy; Endpoints for trials; Human betaretrovirus; Primary biliary cirrhosis; Randomized controlled trial

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; TENOFOVIR; URSODEOXYCHOLIC ACID; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

AUTOIMMUNE BILIARY DISEASE; AUTOIMMUNE LIVER DISEASE; BETARETROVIRUS; BETARETROVIRUS INFECTION; BIOCHEMISTRY; BLOOD; CHOLANGITIS; EXPERIMENTAL MODEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION TEST; MULTICENTER STUDY (TOPIC); NONHUMAN; OPEN STUDY; PILOT STUDY; PRIMARY BILIARY CIRRHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; VIRUS LOAD; ANIMAL; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS, BILIARY; MOUSE; MOUSE MAMMARY TUMOR VIRUS; PATHOGENICITY; VIROLOGY;

ANIMALS; ANTI-RETROVIRAL AGENTS; BETARETROVIRUS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; EMTRICITABINE; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS, BILIARY; LOPINAVIR; MAMMARY TUMOR VIRUS, MOUSE; MICE; TENOFOVIR; ZIDOVUDINE;

EID: 84953380651     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i1.349     Document Type: Review

References (75)

1. Wasilenko ST, Mason GE, Mason AL. Primary biliary cirrhosis, bacteria and molecular mimicry: what's the molecule and where's the mimic? Liver Int 2009; 29: 779-782 [PMID: 19638105]
2. Sharon D, Mason AL. Role of novel retroviruses in chronic liver disease: assessing the link of human betaretrovirus with primary biliary cirrhosis. Curr Infect Dis Rep 2015; 17: 460 [PMID: 25754451 DOI: 10.1007/s11908-014-0460-7]
3. Hirschfield GM, Chapman RW, Karlsen TH, Lammert F, Lazaridis KN, Mason AL. The genetics of complex cholestatic disorders. Gastroenterology 2013; 144: 1357-1374 [PMID: 23583734 DOI: 10.1053/j.gastro.2013.03.053]
4. Mason AL, Zhang G. Linking human beta retrovirus infection with primary biliary cirrhosis. Gastroenterol Clin Biol 2010; 34: 359-366 [PMID: 20580176]
5. Poupon R, Poupon RE. Retrovirus infection as a trigger for primary biliary cirrhosis? Lancet 2004; 363: 260-261 [PMID: 14751695]
6. Mason A, Xu L, Neuberger J. Proof of principal studies to assess the role of the human betaretrovirus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 2499-2500 [PMID: 15571601]
7. Montano-Loza AJ, Wasilenko S, Bintner J, Mason AL. Cyclosporine A inhibits in vitro replication of betaretrovirus associated with primary biliary cirrhosis. Liver Int 2010; 30: 871-877 [PMID: 20492501]
8. Sharon D, Chen M, Zhang G, Girgis S, Sis B, Graham D, McDougall C, Wasilenko ST, Montano-Loza A, Mason AL. Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease. Liver Int 2015; 35: 1442-1450 [PMID: 25302564 DOI: 10.1111/liv.12699]
9. Mason AL, Farr GH, Xu L, Hubscher SG, Neuberger JM. Pilotstudies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 2348-2355 [PMID: 15571581]
10. Mason AL, Lindor KD, Bacon BR, Vincent C, Neuberger JM, Wasilenko ST. Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 2008; 28: 886-894 [PMID: 18627363 DOI: 10.1111/j.1365-2036.2008.03799.x]
11. Mason AL, Montano-Loza AJ, Saxinger L. Letter: biochemical response to combination anti-retroviral therapy in patients with primary biliary cirrhosis. Aliment Pharmacol Ther 2014; 39: 236-237 [PMID: 24330248 DOI: 10.1111/apt.12575]
12. Xu L, Guo L, Shen Z, Loss G, Gish R, Wasilenko S, Mason AL. Duplication of MER115 on chromosome 4 in patients with primary biliary cirrhosis. Liver Int 2009; 29: 375-383 [PMID: 19018986]
13. Mason AL, Xu L, Guo L, Munoz S, Jaspan JB, Bryer-Ash M, Cao Y, Sander DM, Shoenfeld Y, Ahmed A, Van de Water J, Gershwin ME, Garry RF. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet 1998; 351: 1620-1624 [PMID: 9620716]
14. Xu L, Shen Z, Guo L, Fodera B, Keogh A, Joplin R, O'Donnell B, Aitken J, Carman W, Neuberger J, Mason A. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci USA 2003; 100: 8454-8459 [PMID: 12832623]
15. Xu L, Sakalian M, Shen Z, Loss G, Neuberger J, Mason A. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology 2004; 39: 151-156 [PMID: 14752833 DOI: 10.1002/hep.20024]
16. Holland JF, Pogo BG. Mouse mammary tumor virus-like viral infection and human breast cancer. Clin Cancer Res 2004; 10: 5647-5649 [PMID: 15355888]
17. Pogo BG, Holland JF. Possibilities of a viral etiology for human breast cancer. A review. Biol Trace Elem Res 1997; 56: 131-142 [PMID: 9152517]
18. Bentvelzen P. The biology of the mouse mammary tumor virus. Int Rev Exp Pathol 1972; 11: 259-297 [PMID: 4349859]
19. Mason AL. The evidence supports a viral aetiology for primary biliary cirrhosis. J Hepatol 2011; 54: 1312-1314 [PMID: 21147183]
20. Acha-Orbea H, Palmer E. Mls-A retrovirus exploits the immune system. Immunol Today 1991; 12: 356-361 [PMID: 1659830]
21. Johal H, Scott GM, Jones R, Camaris C, Riordan S, Rawlinson WD. Mouse mammary tumour virus-like virus (MMTV-LV) is present within the liver in a wide range of hepatic disorders and unrelated to nuclear p53 expression or hepatocarcinogenesis. J Hepatol 2009; 50: 548-554 [PMID: 19168254]
22. Selmi C, Ross SR, Ansari AA, Invernizzi P, Podda M, Coppel RL, Gershwin ME. Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology 2004; 127: 493-501 [PMID: 15300582]
23. Wang W, Indik S, Wasilenko ST, Faschinger A, Carpenter EJ, Tian Z, Zhang Y, Wong GK, Mason AL. Frequent proviral integration of the human betaretrovirus in biliary epithelium of patients with autoimmune and idiopathic liver disease. Aliment Pharmacol Ther 2015; 41: 393-405 [PMID: 25521721 DOI: 10.1111/apt.13054]
24. Wang W, Wasilenko S, Indik S, Wong G, Mason A. Isolation of the human betaretrovirus and demonstration of integration sites in patients with primary biliary cirrhosis. Canadian J Gastroenterol 2012; 26: 84A
25. McDermid J, Chen M, Li Y, Wasilenko S, Bintner J, McDougall C, Pang X, Bain VG, Mason AL. Reverse transcriptase activity in patients with primary biliary cirrhosis and other autoimmune liver disorders. Aliment Pharmacol Ther 2007; 26: 587-595 [PMID: 17661762 DOI: 10.1111/j.1365-2036.2007.03402.x]
26. Gish RG, Mason A. Autoimmune liver disease. Current standards, future directions. Clin Liver Dis 2001; 5: 287-314 [PMID: 11385965]
27. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010; 52: 745-758 [PMID: 20347176]
28. Joplin R, Gershwin ME. Ductular expression of autoantigens in primary biliary cirrhosis. Semin Liver Dis 1997; 17: 97-103 [PMID: 9170196]
29. Sadamoto T, Joplin R, Keogh A, Mason A, Carman W, Neuberger J. Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis. Lancet 1998; 352: 1595-1596 [PMID: 9843108]
30. Zhang G, Chen M, Graham D, Subsin B, McDougall C, Gilady S, Kneteman M, Law L, Swain M, Trauner M, Wrzesinski S, Flavell R, Wasilenko S, Mason A. Mouse mammary tumor virus in antimitochondrial antibody producing mouse models. J Hepatol 2011; 55: 876-884 [PMID: 21334408]
31. Mason AL. An autoimmune biliary disease mouse model for primary biliary cirrhosis: something for everyone. Hepatology 2006; 44: 1047-1050 [PMID: 17006941]
32. Irie J, Wu Y, Wicker LS, Rainbow D, Nalesnik MA, Hirsch R, Peterson LB, Leung PS, Cheng C, Mackay IR, Gershwin ME, Ridgway WM. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med 2006; 203: 1209-1219 [PMID: 16636131]
33. Koarada S, Wu Y, Fertig N, Sass DA, Nalesnik M, Todd JA, Lyons PA, Fenyk-Melody J, Rainbow DB, Wicker LS, Peterson LB, Ridgway WM. Genetic control of autoimmunity: protection from diabetes, but spontaneous autoimmune biliary disease in a nonobese diabetic congenic strain. J Immunol 2004; 173: 2315-2323 [PMID: 15294944]
34. Wakabayashi K, Lian ZX, Moritoki Y, Lan RY, Tsuneyama K, Chuang YH, Yang GX, Ridgway W, Ueno Y, Ansari AA, Coppel RL, Mackay IR, Gershwin ME. IL-2 receptor alpha(-/-) mice and the development of primary biliary cirrhosis. Hepatology 2006; 44: 1240-1249 [PMID: 17058261]
35. Oertelt S, Lian ZX, Cheng CM, Chuang YH, Padgett KA, He XS, Ridgway WM, Ansari AA, Coppel RL, Li MO, Flavell RA, Kronenberg M, Mackay IR, Gershwin ME. Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 2006; 177: 1655-1660 [PMID: 16849474]
36. Zhang W, Sharma R, Ju ST, He XS, Tao Y, Tsuneyama K, Tian Z, Lian ZX, Fu SM, Gershwin ME. Deficiency in regulatory T cells results in development of antimitochondrial antibodies and autoimmune cholangitis. Hepatology 2009; 49: 545-552 [PMID: 19065675 DOI: 10.1002/hep.22651]
37. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12: 171-181 [PMID: 10714683]
38. Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 2007; 120: 744-750; quiz 751-752 [PMID: 17931557]
39. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995; 3: 521-530 [PMID: 7584142]
40. Young GR, Eksmond U, Salcedo R, Alexopoulou L, Stoye JP, Kassiotis G. Resurrection of endogenous retroviruses in antibodydeficient mice. Nature 2012; 491: 774-778 [PMID: 23103862 DOI: 10.1038/nature11599]
41. Yu P, Lübben W, Slomka H, Gebler J, Konert M, Cai C, Neubrandt L, Prazeres da Costa O, Paul S, Dehnert S, Döhne K, Thanisch M, Storsberg S, Wiegand L, Kaufmann A, Nain M, Quintanilla-Martinez L, Bettio S, Schnierle B, Kolesnikova L, Becker S, Schnare M, Bauer S. Nucleic acid-sensing Toll-like receptors are essential for the control of endogenous retrovirus viremia and ERV-induced tumors. Immunity 2012; 37: 867-879 [PMID: 23142781 DOI: 10.1016/j.immuni.2012.07.018]
42. Held W, Waanders GA, Acha-Orbea H, MacDonald HR. Reverse transcriptase-dependent and-independent phases of infection with mouse mammary tumor virus: implications for superantigen function. J Exp Med 1994; 180: 2347-2351 [PMID: 7525852]
43. Cihlar T. Nucleotide HIV reverse transcriptase inhibitors: tenofovir and beyond. Curr Opin HIV AIDS 2006; 1: 373-379 [PMID: 19372836 DOI: 10.1097/01.COH.0000239849.20828.09]
44. Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006; 130: 715-720 [PMID: 16530513 DOI: 10.1053/j.gastro.2005.12.029]
45. Lammers WJ, Kowdley KV, van Buuren HR. Predicting outcome in primary biliary cirrhosis. Ann Hepatol 2014; 13: 316-326 [PMID: 24927602]
46. Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, Ponsioen CY, Floreani A, Corpechot C, Mayo MJ, Battezzati PM, Parés A, Nevens F, Burroughs AK, Kowdley KV, Trivedi PJ, Kumagi T, Cheung A, Lleo A, Imam MH, Boonstra K, Cazzagon N, Franceschet I, Poupon R, Caballeria L, Pieri G, Kanwar PS, Lindor KD, Hansen BE. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014; 147: 1338-1349.e5; quiz e15 [PMID: 25160979 DOI: 10.1053/j.gastro.2014.08.029]
47. Lammers W, Janssen H, Invernizzi P, Battezzati P, Floreani A, Hirschfield G, Pares A, Ponsioen C, Corpechot C, Mayo M, Talwalkar J, urroughs A, Nevens F, Mason A, Kowdley K, Leeman M, Caballeria L, Trivedi P, Cheung A, Lleo A, Cazzagon N, Franceschet I, Boonstra K, de Vries E, Poupon R, Imam M, Pieri G, Kanwar P, Lindor K, Hansen B. Identification of PBC patients in need of additional therapy during the course of UDCA treatment-An international multicenter study. J Hepatol 2015; 62: S796
48. Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, McCashland TM, Zetterman RK, Peters MG, Di Bisceglie AM, Benner KG, Kowdley KV, Carithers RL, Rosoff L, Garcia-Tsao G, Boyer JL, Boyer TD, Martinez EJ, Bass NM, Lake JR, Barnes DS, Bonacini M, Lindsay KL, Mills AS, Markin RS, Rubin R, West AB, Wheeler DE, Contos MJ, Hofmann AF. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005; 42: 1184-1193 [PMID: 16250039 DOI: 10.1002/hep.20897]
49. Rong J, Chris Bleackley R, Kane KP. Direct detection of cytolytic T lymphocyte-mediated cytotoxicity on antigen-transfected cell microarray. J Immunol Methods 2007; 326: 1-9 [PMID: 17673228 DOI: 10.1016/j.jim.2007.06.008]
50. Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 2010; 52: 349-359 [PMID: 20578151 DOI: 10.1002/hep.23637]
51. Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC, Parés A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E, Böhm O, Shapiro D. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015; 148: 751-761.e8 [PMID: 25500425 DOI: 10.1053/j.gastro.2014.12.005]
52. Suriawinata AA, Thung SN. Liver Pathology: An Atlas and Concise Guide. Demos Medical Publishing, 2011
53. Degott C, Zafrani ES, Callard P, Balkau B, Poupon RE, Poupon R. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999; 29: 1007-1012 [PMID: 10094939]
54. Parés A, Caballería L, Rodés J, Bruguera M, Rodrigo L, García-Plaza A, Berenguer J, Rodríguez-Martínez D, Mercader J, Velicia R. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J Hepatol 2000; 32: 561-566 [PMID: 10782903 DOI: 10.1016/S0168-8278(00)80216-0]
55. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999; 29: 644-647 [PMID: 10051462]
56. Almasio PL, Floreani A, Chiaramonte M, Provenzano G, Battezzati P, Crosignani A, Podda M, Todros L, Rosina F, Saccoccio G, Manenti F, Ballardini G, Bianchi FP, Scheuer PJ, Davies SE, Craxí A. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. Aliment Pharmacol Ther 2000; 14: 1645-1652 [PMID: 11121914 DOI: 10.1046/j.1365-2036.2000.00869.x]
57. Wolfhagen FH, van Hoogstraten HJ, van Buuren HR, van Berge-Henegouwen GP, ten Kate FJ, Hop WC, van der Hoek EW, Kerbert MJ, van Lijf HH, den Ouden JW, Smit AM, de Vries RA, van Zanten RA, Schalm SW. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. J Hepatol 1998; 29: 736-742 [PMID: 9833911]
58. Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2003; 38 Suppl 1: S24-S37 [PMID: 12591184]
59. Oo YH, Neuberger J. Options for treatment of primary biliary cirrhosis. Drugs 2004; 64: 2261-2271 [PMID: 15456326]
60. Crowe J, Christensen E, Smith M, Cochrane M, Ranek L, Watkinson G, Doniach D, Popper H, Tygstrup N, Williams R. Azathioprine in primary biliary cirrhosis: a preliminary report of an international trial. Gastroenterology 1980; 78: 1005-1010 [PMID: 6991353]
61. Hoofnagle JH, Davis GL, Schafer DF, Peters M, Avigan MI, Pappas SC, Hanson RG, Minuk GY, Dusheiko GM, Campbell G. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 1986; 91: 1327-1334 [PMID: 3533699]
62. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335: 1570-1580 [PMID: 8900092]
63. Luketic VA, Invernizzi P, Trauner M, Regula J, Mazzella G, Strasser SI, Floreani A, Hohenester S, van Erpecum KJ, Pockros PJ. Efficacy of Obeticholic Acid In Primary Biliary Cirrhosis as Assessed by Response Criteria Associated With Clinical Outcome: A Poise Analysis. Proceedings of the Hepatology. NJ: Wiley-Blackwell, 2014: 355A-356A
64. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860 [PMID: 9516219]
65. Schembri G, Schober P. Killing two birds with one stone. Lancet 2011; 377: 96 [PMID: 21195252 DOI: 10.1016/s0140-6736(10)61343-8]
66. Nair S, Khan S, Loss G, Eason J, Blazek J, Lipscomb J, Mason A. Treatment of recurrent hepatitis C in liver transplant recipients: is there any histologic benefit? Liver Transpl 2003; 9: 354-359 [PMID: 12682885]
67. McDermid J, Chen M, Li Y, Wasilenko S, Bintner J, McDougall C, Pang X, Bain VG, Mason AL. Reverse transcriptase activity in patients with primary biliary cirrhosis and other autoimmune liver disorders. Aliment Pharmacol Ther 2007; 26: 587-595 [PMID: 17661762]
68. White RA, Quake SR, Curr K. Digital PCR provides absolute quantitation of viral load for an occult RNA virus. J Virol Methods 2012; 179: 45-50 [PMID: 21983150 DOI: 10.1016/j.jviromet.2011.09.017]
69. Strain MC, Lada SM, Luong T, Rought SE, Gianella S, Terry VH, Spina CA, Woelk CH, Richman DD. Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One 2013; 8: e55943 [PMID: 23573183 DOI: 10.1371/journal.pone.0055943]
70. Henrich TJ, Gallien S, Li JZ, Pereyra F, Kuritzkes DR. Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. J Virol Methods 2012; 186: 68-72 [PMID: 22974526 DOI: 10.1016/j.jviromet.2012.08.019]
71. Hayden RT, Gu Z, Ingersoll J, Abdul-Ali D, Shi L, Pounds S, Caliendo AM. Comparison of droplet digital PCR to real-time PCR for quantitative detection of cytomegalovirus. J Clin Microbiol 2013; 51: 540-546 [PMID: 23224089 DOI: 10.1128/JCM.02620-12]
72. Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R, Coltescu C, Heathcote EJ, Hirschfield GM. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105: 2186-2194 [PMID: 20502446]
73. Momah N, Silveira MG, Jorgensen R, Sinakos E, Lindor KD. Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis. Liver Int 2012; 32: 790-795 [PMID: 22136310 DOI: 10.1111/j.1478-3231.2011.02678.x]
74. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-814 [PMID: 19585548 DOI: 10.1002/hep.23082]
75. Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology 2010; 52: 197-203 [PMID: 20564380 DOI: 10.1002/hep.23631]